The dream of biomedical researchers is to fine-tune their therapeutics to precisely target the specific illness or pathogen affecting their patient. Ever since Nobel laureate and oft-quoted father of immunology, Paul Ehrlich, coined the term “magic bullet,” medical science has marched towards more personalized drugs that target key molecules that cause diseases including cancer. ¹ We find ourselves now, over a century later, in an exciting era of discovery that has produced many antibody drug conjugates (ADC) designed to precisely target the diseased cells and not healthy cells. ADC uses this strategy to take advantage of the specificity of antibodies while delivering a covalently linked cytotoxic payload directly to diseased tissues to reduce the multitudes of side effects and toxicity. ^{2, 3} As basic research identifies more targets and antibody engineering procedures improve, the range of antitumor and anti-disease weapons may seem limitless. 

As one of the most common reagents in biology and medical research, there are more than 350,000 commercially produced antibodies available for research and clinical applications. However, the quality of the commercially available antibodies varies from vendor to vendor. Different suppliers have different protocols for validating antibodies and some researchers might want to verify the product before using them on precious samples. Here are some of the factors to examine when it comes to antibody quality.